<DOC>
	<DOCNO>NCT02450682</DOCNO>
	<brief_summary>This study do determine apixaban safe , compare warfarin , reduce risk bleed CIED procedure .</brief_summary>
	<brief_title>Apixaban Patients Who Undergo CIED Procedure- Randomized Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Signed informed write consent 2 . Patients take warfarin apixaban chronically 3 . Patients risk stroke systemic embolism 4 . Patients NVAF 5 . Patients undergo CIED generator change 6 . Age 1890 7 . Either gender 8 . All eligibility criterion must meet Exclusion : 1 . Patient critically ill , unstable condition 2 . Patient high risk bleeding , HASBLED score â‰¥ 3 3 . Patient required take dual antiplatelet agent addition anticoagulant drug . ( e.g . recent cardiac stent placement ) 4 . Patients mechanical cardiac valve another condition NVAF require chronic anticoagulation 5 . Women childbearing potential positive pregnant test 6 . Bilirubin &gt; 2x upper limit normal , association AST/ALT/ALP &gt; 3x upper limit normal 7 . Allergy apixaban warfarin 8 . Subjects require take strong dual inhibitor CYP3A4 Pgp already meet criterion take 2.5 mg apixaban 9 . Subjects require take strong dual inducer CYP3A4 Pgp ( .e.g. , rifampin , carbamazepine , phenytoin , St. John 's wort ) 10 . Patients take investigational drug within 30 day enrol study . 11 . Prisoners subject involuntarily incarcerate . 12 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>